Oslo Cancer Cluster is a non-profit member organization dedicated to accelerate the development of new cancer therapeutics and diagnostics. The cluster’s biotechs and academic Centers of Excellence are developing a growing pipeline of preclinical and clinical product candidates mainly in Immuno-Oncology and Precision Oncology.
The cluster has > 75 members covering the entire value chain and includes academic centers, university hospitals, technology transfer organizations, start-ups, biotechs and international pharma companies, service providers as well as investors.
Focus of the cluster management is on innovation, collaboration and partnering as well as capital development. To support the business development activities of its members the cluster is building relationships with scouting, licensing and BD executives from international pharma and biotech companies and with life science investors.
The Oslo Cancer Cluster Incubator AS is integral part of the Oslo Cancer Cluster Innovation Park. It provides a dynamic growth environment for scientists and start-ups. A dedicated team supports the tenants with business development services, provides access to an extensive international oncology R&D network, and facilitates investor contacts.
The Incubator’s 35 tenants include academic groups, technology transfer organizations, start-ups, biotechs and international pharma, service providers and investors benefitting from physical infrastructure, flexible meeting space and an extensive joint network.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.